• Home
  • About
    • Epitracker Team
    • Discovery Process
  • ONE HEALTH: DOLPHINS & HUMANS
  • Focus Areas
    • Healthy Aging & Longevity
    • Neurodegenerative Diseases
    • Fibrotic Diseases
    • Pulmonary Diseases
    • MicroRNA & Gene Therapies
    • Animal Health
  • News
  • Contact Us

discovery process

Picture
Epitracker's unique discovery process featured in XConomy Insight Webinar.  Click below to register and watch the taped session.
WATCH THE WEBINAR
Epitracker leverages genomic, metabolomic, and complex lipidomic data from previously collected and archived dolphin samples to discover novel small molecule therapeutics that may continually improve the health and welfare of dolphins and humans across four primary programs​​:  Longevity, Neurodegenerative Diseases, Fibrotic Diseases, and Pulmonary Diseases.

Read below to learn how Epitracker discovers and screens its compounds.

Step 1: ​ Screen for Promising Molecules

Our discovery process starts with the analysis of millions of metabolomic, lipid, genomic and clinical data points generated from previously collected, archived dolphin samples using tiered statistical models to prioritize which small molecules predict healthy dolphins. This prioritization is based on each molecule's potential as a candidate therapeutic, therapeutic target, and/or biomarker across our discovery programs. These 'smart screened' molecules become part of Epitracker's rapidly expanding compound libraries that are further screened, prioritized and advanced as therapeutic candidates.
Picture

Step 2: Prioritize and Place  Molecules in Compound Libraries

Epitracker's discovery platform has yielded hundreds of promising molecules across more than 30 pathways. These compounds include lipids, amino acids, and other molecules that are known or expected to be present in human serum. 

Today, Epitracker has compound libraries for longevity, neurodegenerative diseases, nonalcoholic steatohepatitis, and pulmonary diseases.
Picture

Step 3: ​Test Molecules for Activity & Efficacy

Once Epitracker's smart-screened molecules have been prioritized and placed into a compound library, we advance them through our discovery-to-product process. To date, 18 of 20 - that's an impressive 90%  of our molecules tested - have successfully demonstrated desired dose-response activity in human cell systems. Based on encouraging cell-based activity, mechanism of action, associated genetic & pathway, and bench marking data, eight of our compounds are being advanced through the appropriate Epitracker program.
Picture
HOME
ABOUT US
    Epitracker Team
    Discovery Process
ONE HEALTH: Dolphins & Humans

FOCUS AREAS
   Healthy Aging & Longevity
   Neurodegenerative Diseases
   Fibrotic Diseases
   Pulmonary Diseases
   MicroRNA & Gene Therapies
   Animal Health
NEWS
SPINOUT COMPANY: SERAPHINA THERAPEUTICS
CONTACT US
  • Home
  • About
    • Epitracker Team
    • Discovery Process
  • ONE HEALTH: DOLPHINS & HUMANS
  • Focus Areas
    • Healthy Aging & Longevity
    • Neurodegenerative Diseases
    • Fibrotic Diseases
    • Pulmonary Diseases
    • MicroRNA & Gene Therapies
    • Animal Health
  • News
  • Contact Us